Desmopressin - A haemostatic drug: State-of-the-art review

European Journal of Anaesthesiology, Supplement

Volumn 14, Issue 4, 1997, Pages 1-9

  Lethagen, S ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Blood; Desmopressin; Factor VIII; Haemophilia; Pharmacology; Platelet dysfunction; Surgery; Von Willebrand's disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; HEMOSTATIC AGENT; NEUROHYPOPHYSIS HORMONE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLEEDING TENDENCY; CONFERENCE PAPER; DRUG TOLERABILITY; HEADACHE; HEMOPHILIA A; HEMOSTASIS; HOT FLUSH; HYPOTENSION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ADHESIVENESS; THROMBOCYTE DYSFUNCTION; VON WILLEBRAND DISEASE;

DEAMINO ARGININE VASOPRESSIN; HEMORRHAGE; HEMOSTATICS; HUMANS;

EID: 0030729382     PISSN: 09521941     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Zaoral M, Kole J, Sorm F. Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-amino-butyrine vasopressin, 1-deamino-8-D-lysine vasopressin and 1-deamino-8-D-arginine vasopressin. Collection Czechoslov Chem Commun 1967; 32: 1250-1257.
2. Ingram GIC. Increase in antihaemophilic globulin activity following infusion of adrenaline. J Physiol 1961; 156: 217-224.
3. Egeberg O. Changes in the activity of antihemophilic A factor (f.VIII) and in the bleeding time associated with muscular exercise and adrenaline infusion. Scand J Clin Lab Invest 1963; 15: 539.
4. Schneck S, von Kaulla KN. Fibrinolysis and the nervous system. Neurology (Minneapolis) 1961; 11: 959.
5. Mannucci PM, Gagnatelli G, D'Alonzo R. Stress and blood coagulation. In: Brinkhous KM, Hinnom S, eds. Thrombosis: Risk factors and diagnostic approaches. Stuttgart: Schattauer Verlag 1972; 105-110.
6. Kobrinsky NL, Doyle JJ, Israels EDS et al. Absent factor VIII response to synthetic vasopressin analogue in nephrogenic diabetes inspidus. Lancet 1985; i: 1293-1294.
7. Bichet DG, Razi M, Lonergan M et al. Hemodynamic and coagulation responses to 1-deamino [8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus New Engl J Med 1988; 318: 881-887.
8. Mannucci PM, Åberg M, Nilsson IM, Robertsson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
9. Brenner B, Seligsohn U, Hochberg Z. Normal response of factor VIII and von Willebrand factor to 1-deamino-8-D-arginine vasopressin in nephrogenic diabetes insipidus. J Clin Endocrinol Metab 1988; 67: 191-193.
10. Ohzcki T, Sunaguchi M, Tsunei M et al. Coagulation factor responsiveness in nephrogenic diabetes insipidus. J Pediatrics 1988; 113: 790.
11. Mannucci PM. Desmopressin (DDAVP) for treatment of disorders of hemostasis. In: Coller BS, ed. Progress in Hemostasis and Thrombosis. Orlando: Grune & Stratton, Inc. 1986: 19-45.
12. Nilsson IM, Mikaelsson M, Vilhardt H. The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons. Scand J Haematol 1982; 29: 70-74.
13. Stel HV, van der Kwast ThH, Veerman ECI. Detection of factor VIII/coagulant antigen in human liver-tissue. Nature 1983; 303: 530-532.
14. Wion KI, Kelly D, Summer-field JA, Tuddenham EGD, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-729.
15. Zelechowska MG, van Mourik JA, Brodniewicz-Porba T. Ultrastructural localization of factor VIII procoagulant antigen in human lives hepatocytes. Nature 1985; 317: 729-730.
16. Howard MA, Montgomery DC, Hardisty RM. Factor VIII-related antigen in platelets. Thromb Res 1974; 4: 617-624.
17. Nachman RL, Jaffe EA. Subcellular platelet factor VIII antigen and von Willebrand factor. J Exp Med 1975; 141: 1101-1113.
18. Booyse FM, Osikowicz G, Feder S. Effects of various agents on ristocetin-Willebrand factor activity in long-term cultures of von Willebrand and normal human umbilical vein endothelial cells. Thromb Haemostas 1981; 46: 668.
19. Tuddenham EGD, Lane RS, Rotblat F et al. Response to infusions of poly electrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 1982; 52: 259-267.
20. Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D. Correction by factor VIII of the impaired platelet adhesion to subendothelium in von Willebrand's disease. Blood 1978; 51: 267-279.
21. Sakariassen KS, Cattaneo M, van den Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 229-236.
22. Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention. Its dependence on platelet-von Willebrand factor and the platelet receptor GPIIb/IIIa. Eur J Haematol 1992; 49: 7-13.
23. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects, and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981; 47: 283-293.
24. Lethagen S, Harris AS, Sjörin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: Effect on fVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemostas 1987; 58: 1033-1036.
25. Kohler M, Hellstern P, Miyashita C, von Blohm G, Wenzel I. Comparative study of intranasal subcutaneous and intravenous administration of deamino D-arginine vasopressin (DDAVP). Thromb Haemostas 1986; 55: 108-111.
26. Kohler M, Mariani G. Intravenous and subcutaneous desmopressin. Clinical results. In: Mariani G, Mannucci PM, Cattaneo M, eds. Desmopressin in Bleeding Disorders. New York: Plenum Press 1993; 309-316.
27. Harris AS, Nilsson IM, Wagner ZG, Alkner U. Intranasal administration of peptides. Nasal deposition, biological response and absorption of desmopressin. J Pharm Sci 1986; 75: 1085-1088.
28. Lethagen S, Egervall K, Berntorp E, Bengtsson B. Desmopressin nasal spray. A dose-finding study in patients with mild hemophilia A and von Willebrand's disease. Haemophilia 1995; 1: 97-102.
29. McLellan DS, Knight S, McLellan HG, Wassef M, Aronstam A. The influence of DDAVP on the survival of factor VIII in severe hemophiliacs. Thromb Res 1985; 40: 113-119.
30. Nilsson IM, Felding P, Timberg L, Jonsson S, Harris AS. Clinical experience with DDAVP. In: Ciavarella NL, Ruggen Z, Zimmerman TS, eds. Factor VIII von Willebrand factor. Biological and clinical advances. Proceedings of Barr International Conference. Milan: Wichtig Editore 1986; 63-80.
31. Nilsson IM, Lethagen S. Current status of DDAVP formulations and their use. In: Lusher JM, Kessler CM, eds. Hemophilia and von Willebrand's disease in the 1990's. Amsterdam: Elsevier Science Publishers B.V. 1991; 443-453.
32. Kobrinsky NI, Israels ED, Gerrard JM et al. Shortening of the bleeding time by 1-deamine-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984; i: 1145-1148.
33. Winckelman G, Augustin R. Improvement of primary hemostasis by DDAVP in patients with various platelet defects. Thromb Haemostas 1985; 54: 12.
34. Marti GE, Rick MF, Sidbury J, Gralsnick HR. DDAVP infusion in five patients with type 1a glycogen storage disease and associated correction of prolonged bleeding times. Blood 1986; 68: 180-184.
35. Mannucci PM, Vicente V, Vianello L et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with prolonged bleeding time. Blood 1986; 67: 1148-1153.
36. Schulman S, Johnsson H, Egberg N, Blomback M. DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thromb Res 1987; 45: 165-174.
37. Kentro TB, Lottenberg R, Kitchens CS. Clinical efficacy of desmopressin acetate for hemostatic control in patients with primary platelet disorders undergoing surgery. Am J Hematol 1990; 24: 215-219.
38. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33: 39-45.
39. Lethagen S, Rugam P. The effect of DDAVP and placebo on platelet function and prolonged bleeding time induced by oral acetylsalicylic acid treatment in healthy volunteers. Thromb Haemostas 1992; 67: 185-186.
40. Kim HC, Salva KS, Fallot PL et al. Patients with prolonged bleeding time of undefined etiology and their response to desmopressin. Thromb Haemostas 1988; 59: 221-224.
41. Mikaelsson M, Nilsson IM, Vilhardt H, Wiechel B. Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of vasopressin analogue. Transfusion 1982; 22: 229-233.
42. Palmer DS, Harris AS, Tittley P, Rock G. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors. Haemostasis 1988; 18: 187-196.
43. Salzman EW, Weinstein MJ, Weintraub RM et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomised trial. New Engl J Med 1986; 314: 1402-1406.
44. Kobrinsky NI, Letts RM, Patel LR, Israels ED, Monson RC, Schwetz N, Cheang MS. 1-deamino-8-D-arginine vasopressin (desmopressin) decreases operative blood loss in patients having Harrington rod spinal fusion surgery. A randomised, double-blinded, controlled trial. Ann Intern Med 1987; 107: 446-450.
45. Rocha E, Llorens R, Paramo JA, Areas R, Cuesta B, Trenor AM. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 1988; 77: 1319-1323.
46. Hackman T, Gascoyne RD, Naiman SC et al. A trial of desmopressin (1-deamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. New Engl J Med 1989; 321: 1437-1443.
47. Lazenby WD, Russo I, Zadeh BJ et al. Treatment with desmopressin acetate in routine artery bypass surgery to improve postoperative hemostasis. Circulation 1990; 82 (Suppl. IV): 413-419.
48. Lo Cicero J, Massad M, Matano J. Effect of desmopressin acetate on hemorrhage without identifiable cause in coronary bypass patients. The American Surgeon 1991; 53: 165-168.
49. Horrow JC, van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 1991; 84: 2063-2070.
50. Guay J, Remberg C, Rivard GE, Poitras B, Mathews S, David M. DDAVP does not reduce bleeding during spinal fusion for idiopathic scoliosis. Can J Anaesth 1990; 37: 14.
51. Cattaneo M, Mannucci PM. Desmopressin and blood loss after cardiac surgery. Lancet 1993; 342: 812.
52. Czer LSC, Bateman TM, Gray RJ et al. Treatment of severe platelet dysfunction and hemorrhage after cardiopulmonary bypass: reduction in blood product usage with desmopressin. J Am Coll Cardiol 1987; 9: 1139-1147.
53. Mongan PD, Hosking MP. The role of desmopressin acetate in patients undergoing coronary artery bypass surgery. A controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992; 77: 38-46.
54. Gratz I, Koehler J, Olsen D et al. The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. J Thorac Cardiovasc Surg 1992; 104: 1417-1422.
55. Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild haemophilia A and von Willebrand's disease type 1. Blut 1990; 60: 187-191.
56. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand's disease. Ann Intern Med 1991; 114: 563-568.
57. Lethagen S, Ragnarson-Tenvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders. Effect on bleeding symptoms and socio-economic factors. Ann Hematol 1993; 66: 257-260.
58. Mannucci PM, Bettega D, Cattaneo M. The development of tachyphylaxis in patients with haemophilia and von Willebrand's disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82: 87-93.
59. Mannucci PM. Desmopressin: A nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-1455.
60. Lowe G, Pettigrew A, Middleton S, Forbes CD, Prentice CRM. DDAVP in haemophilia. Lancet 1977; 2: 614-615.
61. Koskimies O, Pylkkänen J, Vilska J. Water intoxication in infants caused by the urine concentration test with vasopressin analogue (DDAVP). Acta Paediatr Scand 1984; 73: 131-132.
62. De la Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann Intern Med 1985; 103: 6-14.
63. Sheperd LL, Hutchinson RJ, Worden EK, Koopman CF, Coran A. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114: 470-472.
64. Weinstein RE, Bona RD, Altman AJ, et al. Severe hyponatremia after repeat intravenous administration of desmopressin. Am J Hematol 1989; 32: 258-261.
65. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199-202.
66. Salvatoni A, Maghnie M, Lorini R, Marni E. Hyponatremia and seizures during desmopressin acetate treatment in hypothyroidism. J Pediatr 1990; 116: 835-836.
67. Binch LIC, Jacobsen MB. Hyponatremi ved behandling av von Willebrands sykdom. Tidsskr Nor Laegeforen 1992; 112: 3670-3671.
68. Beach PS, Beach RE, Smith IR. Hyponatremic seizures in a child treated with desmopressin to control enuresis. A rational approach to fluid intake. Clin Pediatr Philadelph 1992; 31: 566-569.
69. Yaouyanc G, Jonville AP, Yaouyanc-Lapalle H, Barbier P, Dutertre JP, Autret E. Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis. J Toxicol Clin Toxicol 1992; 40: 637-641.
70. Humphries KE, Siragy H. Significant hyponatremia following DDAVP administration in a healthy adult. Am J Hematol 1993; 44: 12-15.
71. O'Brien JR, Green PJ, Salmon G et al. Desmopressin and myocardial infarction. Lancet 1989; i: 664.
72. Van Dantzig JM, Duren DR, ten Cate JW. Desmopressin and myocardial infarction. Lancet 1989; i: 664.
73. Bond I, Bevan DU. Myocardial infarction in a patient with hemophilia treated with DDAVP. New Engl J Med 1988; 318: 121.
74. Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989; ii: 675-676.
75. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemostas 1994; 71: 154-155.
76. Castaman G, Rodeghiero F. Desmopressin and type IIB von Willebrand disease. Haemophilia 1996; 2: 73-77.